Wright C S, Steele S J, Jacobs H S
Br Med J. 1979 Apr 21;1(6170):1037-9. doi: 10.1136/bmj.1.6170.1037.
In a double-blind controlled study, 47 women with unexplained primary infertility were allocated at random to treatment with either bromocriptine 2.5 mg twice daily (24 patients) or placebo (23). Both groups showed a fall in serum prolactin concentrations but the reduction was much greater in the bromocriptine-treated group. Neither group showed a change in serum oestrogen or progesterone concentrations. Bromocriptine significantly reduced the duration of the follicular phase of the menstrual cycle but had no effect on the luteal phase. Five women conceived during treatment with placebo and seven during treatment with bromocriptine, but analysis of the cumulative conception rates showed no significant difference between the groups. The women who conceived were significantly younger and had a significantly shorter history of infertility than the women who did not conceive, but subtracting the number of years of infertility from age eliminated this difference. The results show that bromocriptine in the dose and duration of administration used in the trial is of no value in unexplained primary infertility.
在一项双盲对照研究中，47名不明原因的原发性不孕女性被随机分为两组，一组每日两次服用2.5毫克溴隐亭（24例患者），另一组服用安慰剂（23例）。两组血清催乳素浓度均下降，但溴隐亭治疗组的下降幅度更大。两组血清雌激素或孕酮浓度均无变化。溴隐亭显著缩短了月经周期的卵泡期，但对黄体期无影响。安慰剂治疗期间有5名女性怀孕，溴隐亭治疗期间有7名女性怀孕，但累积受孕率分析显示两组之间无显著差异。怀孕的女性比未怀孕的女性明显年轻，不孕病史也明显更短，但从年龄中减去不孕年限后消除了这种差异。结果表明，试验中使用的溴隐亭剂量和给药持续时间对不明原因的原发性不孕没有价值。
